Study Finds Factors That May Accurately Forecast Onset of Psychiatric Disorders

New research has found evidence that an extensive range of early onset psychiatric issues like ADHD, bulimia, dyslexia, anxiety and depression are primarily caused by psychological, social and biological factors.

The objective of the study, which was conducted by scientists at McGill University, was to better understand the cause of psychiatric disorders.

With regard to the factors that may cause these disorders to develop, the psychological factor is associated with temperament, in particular, difficulty controlling emotions and the tendency toward impulsivity. The social factor suggests the crucial role of early childhood abuse or neglect while the biological factor is in the form of individual variability in the dopamine reward pathway in the brain.

The researchers believe that their discoveries have implications for understanding the factors that should be targeted during early intervention as well as the cause of an extensive range of psychiatric disorders.

Marco Leyton, a professor from the institution’s Department of Psychiatry, stated that this research suggested that most early-onset disorders primarily reflected distinctive expressions of a small number of social, psychological and biological factors. He noted that this was different from earlier hypotheses by researchers which suggested that the disorders reflected different illness entities. Prior research has also proposed that each of the aforementioned factors has, at the very least, moderate effects on psychiatric disorder development.

For their study, the researchers recruited 52 young individuals living in the Quebec City or Montreal areas who had been followed since birth by Michel Boivin and Jean Séguin. Both Boivin and Séguin are researchers from Université Laval and Université de Montréal, respectively.

Each participant had MRI and PET scans that measured features of their dopamine reward pathway taken. The brain imaging scans were then combined with data on the participants’ histories of early life adversity and temperamental traits in order to assess for the factors mentioned above.

The researchers found that the combination of these factors forecasted which participants had mental health issues with 90% accuracy. The study’s findings are so new and potentially important that the researchers have been granted additional funding to carry it out with a larger sample size. The first author of the study, Maisha Iqbal, stated that the study’s results need to be replicated in bigger and more ethnically diverse groups, because those results may change the way we view mental health conditions.

Other researchers involved in the study include Richard E. Tremblay, Sylvana M. Côté, Frank Vitari, Alain Dagher and Natalia Jaworska, among others. The study’s findings were reported in the “Neuropsychopharmacology” journal.

Mental health is attracting a lot of interest in the research community, and companies such as Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) are focused on coming up with new formulations that will mark a paradigm shift from the way these conditions have been managed for decades.

NOTE TO INVESTORS: The latest news and updates relating to Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) are available in the company’s newsroom at https://ibn.fm/MYCOF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.